Italian Trade Agency at Arab Health supports 160 companies

By HEOR Staff Writer

February 1, 2023

Introduction:

The Italian Trade Agency (ITA) is a government entity promoting Italian products and services. It has thrown its weight behind 160 Italian companies participating in Arab Health 2023.

Arab Health 2023: A Global Healthcare Stage

Arab Health, an annual event that congregates healthcare professionals and companies globally. It is a platform to exhibit the latest products, services, and technological advancements in the healthcare industry. This year’s event, held in Dubai from 30th January to 2nd February, presents a spectrum of healthcare offerings, including innovations like artificial intelligence.

Italian Trade Agency at Arab Health

Located across four different halls, the Italian Pavilion provides a snapshot of Italy’s manufacturing capabilities in the healthcare sector. The pharmaceutical sector, boasting 285 companies employing 67,000 people, stands out for having the most innovative companies. The Italian pharmaceutical industry demonstrates particular prowess in biotech drugs and vaccines. Therefore, establishing Italy as a global hub for research and development (R&D) and production.

Italy’s Vision for the UAE and Sustainability Goals

Lorenzo Fanara, Italy’s Ambassador to the United Arab Emirates (UAE), and Amedeo Scarpa, Italian Trade Commissioner to the UAE, expressed Italy’s vision to strengthen business ties with the UAE, foster long-term investments, and develop industrial partnerships. Under the banner ‘Sustainability is Sustainab-ITALY’, Arab Health 2023 will focus on circular economy and sustainability, reflecting Italy’s pharmaceutical industry’s achievement in reducing energy consumption by 44% over a decade.

Conclusion:

Italian Trade Agency at Arab Health’s support for Italian healthcare companies reflects its commitment to promoting Italy’s robust healthcare sector and its vision for sustainable growth.

Reference url

Recent Posts

Paving the Way for Digital Health Technologies: NICE’s Bold New Strategy for the NHS

By HEOR Staff Writer

October 9, 2025

The National Institute for Health and Care Excellence (NICE) is expanding its technology appraisals programme, and starting April 2026, this will include digital health technologies that are placed on an equal legal footing with medicines in the NHS. This initiative forms part of the NHS 10-year ...
Health Misinformation Autism: The Dangers of Politicized Science in Vaccine and Drug Discourse

By João L. Carapinha

October 7, 2025

The BMJ article “Tylenol, vaccines, and autism: the medical mayhem of the MAGA methodologists” argues that political and ideological actors, notably aligned with the MAGA movement, are promoting health misinformation about autism, vaccines, and paracetamol. They amplify preliminary, misinterprete...
Lurbinectedin SCLC Therapy: FDA Approval and Its Economic Implications

By João L. Carapinha

October 6, 2025

The U.S. Food and Drug Administration (FDA) has recently approved lurbinectedin SCLC therapy in combination with atezolizumab, or with atezolizumab and hyaluronidase-qvfc, for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). This regulatory decision reflects ...